Replies to post #80158 on Biotech Values

[DewDiligence]

MYL-Biocon FoB portfolio:

• Herceptin: phase-1
• Neulasta: preclinical
• Avastin: process development
• Humira: cell-line development
• Enbrel*: cell-line development
• One undisclosed product at an undisclosed stage

*Presumably not for US market due to AMGN’s recent patent extension.

Source: MYL’s Investor Day webcast (2/21/12).

[DewDiligence]

Roche wins India injunction against MYL/Biocon’s comparing their Herceptin FoB to branded Herceptin:

http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/roche-sues-biocon-mylan-dcgi-over-breast-cancer-drug/articleshow/29966468.cms

The FoB market in India is muddied by the lack of patent protection for many branded drugs, including Herceptin. Roche couldn’t sue to block the actual selling of MYL/Biocon’s Herceptin FOB, and hence Roche had to resort to impeding MYL/Biocon’s marketing message.

This case should not be considered a harbinger of what will occur to FoB’s in the US, where the regulations are much different than in India.